salicylic acid has been researched along with Neuralgia in 24 studies
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This was done by comparing skin and plasma levels of acetylsalicylic acid (ASA) and salicylic acid (SA) after topically administered ASA/diethyl ether (ADE) mixture in acute herpetic neuralgia (AHN) and postherpetic neuralgia (PHN)." | 9.08 | Skin and plasma levels of acetylsalicylic acid: a comparison between topical aspirin/diethyl ether mixture and oral aspirin in acute herpes zoster and postherpetic neuralgia. ( Bareggi, SR; De Benedittis, G; Pirola, R, 1998) |
| " This was done by comparing skin and plasma levels of acetylsalicylic acid (ASA) and salicylic acid (SA) after topically administered ASA/diethyl ether (ADE) mixture in acute herpetic neuralgia (AHN) and postherpetic neuralgia (PHN)." | 5.08 | Skin and plasma levels of acetylsalicylic acid: a comparison between topical aspirin/diethyl ether mixture and oral aspirin in acute herpes zoster and postherpetic neuralgia. ( Bareggi, SR; De Benedittis, G; Pirola, R, 1998) |
| "Most scalp neuralgias are supraorbital or occipital." | 2.50 | [Scalp neuralgia and headache elicited by cranial superficial anatomical causes: supraorbital neuralgia, occipital neuralgia, and post-craniotomy headache]. ( Shimizu, S, 2014) |
| "Occipital neuralgia is a benign extracranial cause of headache, and it may be confused with other more serious headache syndromes." | 2.40 | Occipital neuralgias: clinical recognition of a complicated headache. A case series and literature review. ( Gilberstadt, H; Kuhn, SC; Kuhn, WF, 1997) |
| "A 46-year-old female, known case of adiposis dolorosa since adolescence, noticed painful thickening of scalp in bilateral parieto-occipital areas and vertex 1 year back." | 1.36 | Adiposis dolorosa of scalp presenting with severe headache: an unusual case. ( Bhoyar, K; Dange, N; Kawale, J; Mahore, A, 2010) |
| "We believed that the loss of consciousness during lesser nerve block may be due to a subarachnoid injection." | 1.31 | Sudden unconsciousness during a lesser occipital nerve block in a patient with the occipital bone defect. ( Kim, P; Kitajima, T; Matsumoto, T; Okuda, Y; Shinohara, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (33.33) | 18.7374 |
| 1990's | 7 (29.17) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 5 (20.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| LUDECKE, T | 1 |
| Bareggi, SR | 1 |
| Pirola, R | 1 |
| De Benedittis, G | 1 |
| Wang, L | 1 |
| Das, S | 1 |
| Yang, H | 1 |
| Shimizu, S | 1 |
| Doh, EJ | 1 |
| Yoon, HS | 1 |
| Cho, S | 1 |
| Park, HS | 1 |
| Cohen, SP | 1 |
| Peterlin, BL | 1 |
| Fulton, L | 1 |
| Neely, ET | 1 |
| Kurihara, C | 1 |
| Gupta, A | 1 |
| Mali, J | 1 |
| Fu, DC | 1 |
| Jacobs, MB | 1 |
| Plunkett, AR | 1 |
| Verdun, AJ | 1 |
| Stojanovic, MP | 1 |
| Hanling, S | 1 |
| Constantinescu, O | 1 |
| White, RL | 1 |
| McLean, BC | 1 |
| Pasquina, PF | 1 |
| Zhao, Z | 1 |
| Klinger, M | 1 |
| Villani, F | 1 |
| Klinger, F | 1 |
| Gaetani, P | 1 |
| Rodriguez Y Baena, R | 1 |
| Levi, D | 1 |
| Kawale, J | 1 |
| Mahore, A | 1 |
| Dange, N | 1 |
| Bhoyar, K | 1 |
| Wang, H | 1 |
| Chen, H | 1 |
| Jiang, H | 1 |
| Cerrato, P | 1 |
| Bergui, M | 1 |
| Imperiale, D | 1 |
| Baima, C | 1 |
| Grasso, M | 1 |
| Giraudo, M | 1 |
| Lentini, A | 1 |
| Lopiano, L | 1 |
| Bradac, GB | 1 |
| Bergamasco, B | 1 |
| MARTIN, BC | 1 |
| FAGAN, PJ | 1 |
| Oh, S | 1 |
| Tok, S | 1 |
| Allemann, J | 1 |
| Prevost, A | 1 |
| Schmid, UD | 1 |
| Mathur, JG | 1 |
| Rifat, SF | 1 |
| Lombardo, JA | 1 |
| Dubuisson, D | 1 |
| Sulfaro, MA | 1 |
| Gobetti, JP | 1 |
| Brown, CR | 1 |
| Kuhn, WF | 1 |
| Kuhn, SC | 1 |
| Gilberstadt, H | 1 |
| Okuda, Y | 1 |
| Matsumoto, T | 1 |
| Shinohara, M | 1 |
| Kitajima, T | 1 |
| Kim, P | 1 |
| Schultz, DR | 1 |
| Thomas, AL | 1 |
| Xie, Z | 1 |
| Graff-Radford, SB | 1 |
| Jaeger, B | 1 |
| Reeves, JL | 1 |
| Dalessio, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Heated vs. Pulsed Radiofrequency Treatment of the Genicular Nerves for Osteoarthritis Knee Pain[NCT04379895] | 60 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | |||
| A Comparison of Pain Control AND Quality of Life Improvement Between Occipital Nerve Block And Occipital Nerve Radiofrequency Ablation: A Double-Blind Single Center Prospective Study[NCT04124458] | 70 participants (Anticipated) | Interventional | 2023-01-02 | Not yet recruiting | |||
| Pulsed vs Continuous Radiofrequency Neurotomy for Cervical Facet Joint Mediated Pain: a Single-blind Randomized Controlled Clinical Trial[NCT04124445] | 88 participants (Anticipated) | Interventional | 2020-02-10 | Recruiting | |||
| Randomized, Double-blind, Comparative-effectiveness Study Comparing Corticosteroid Injections to Pulsed Radiofrequency for Occipital Neuralgia[NCT01670825] | 81 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
| Greater Occipital Nerve Pulsed Radiofrequency for the Treatment of Combined Migraine and Cervicogenic Headache (New Approach): Randomized Clinical Trial[NCT06121037] | 60 participants (Actual) | Interventional | 2022-01-01 | Completed | |||
| Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia: A Randomized Controlled Pilot Study[NCT04051203] | Phase 1 | 35 participants (Anticipated) | Interventional | 2019-02-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.495 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 3.694 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.791 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.441 |
The change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.312 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.765 |
The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.068 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 3.738 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.392 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.220 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.000 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.694 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.761 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.556 |
This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.678 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.410 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.540 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.650 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.522 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.417 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.761 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.556 |
This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.583 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.825 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 9.539 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 9.069 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 9.256 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 9.431 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 10.025 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 8.132 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 11.333 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 11.972 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 12.590 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 12.250 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 12.775 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 10.842 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.726 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 5.846 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.850 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.149 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.705 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.541 |
The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.354 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.064 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 59.718 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 60.556 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 59.641 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 61.389 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 60.087 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 59.553 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 3 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.087 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.263 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.044 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.368 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.708 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.810 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: 3 months
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.846 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.919 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.128 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.162 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.436 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.436 |
3 reviews available for salicylic acid and Neuralgia
| Article | Year |
|---|---|
[Scalp neuralgia and headache elicited by cranial superficial anatomical causes: supraorbital neuralgia, occipital neuralgia, and post-craniotomy headache].
Topics: Craniotomy; Decompression, Surgical; Headache; Humans; Neck Muscles; Neuralgia; Orbit; Peripheral Ne | 2014 |
Occipital neuralgia manifesting as orofacial pain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Facial Pain; Female; Humans; Middle Aged; | 1995 |
Occipital neuralgias: clinical recognition of a complicated headache. A case series and literature review.
Topics: Adult; Anesthetics, Local; Diagnosis, Differential; Facial Pain; Female; Follow-Up Studies; Headache | 1997 |
2 trials available for salicylic acid and Neuralgia
19 other studies available for salicylic acid and Neuralgia
| Article | Year |
|---|---|
[Therapy of rheumatic, neuralgic and influenzal diseases in general practice].
Topics: Family Practice; General Practice; Humans; Influenza, Human; Neuralgia; Phenacetin; Rheumatic Diseas | 1953 |
DTI of great occipital nerve neuropathy: an initial study in patients with cervicogenic headache.
Topics: Adult; Aged; Aged, 80 and over; Diffusion Tensor Imaging; Feasibility Studies; Female; Humans; Male; | 2019 |
Occipital neuralgia after scalp biopsy and curettage.
Topics: Biopsy; Curettage; Female; Headache Disorders; Humans; Hypotrichosis; Middle Aged; Neuralgia; Scalp; | 2015 |
Anatomical variations of the occipital nerves: implications for the treatment of chronic headaches.
Topics: Cicatrix; Cranial Nerves; Decompression, Surgical; Headache Disorders; Humans; Neuralgia; Occipital | 2009 |
Adiposis dolorosa of scalp presenting with severe headache: an unusual case.
Topics: Adiposis Dolorosa; Diagnosis, Differential; Female; Headache Disorders; Humans; Middle Aged; Neuralg | 2010 |
Experience in acupuncture treatment of occipital neuralgia.
Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Neuralgia; Occipita | 2002 |
Occipital neuralgia as isolated symptom of an upper cervical cavernous angioma.
Topics: Female; Hemangioma, Cavernous, Central Nervous System; Humans; Middle Aged; Neuralgia; Radiography; | 2002 |
THE SURGICAL THERAPY OF CERTAIN OCCIPITAL HEADACHES.
Topics: Headache; Humans; Neuralgia; Neurosurgery; Neurosurgical Procedures; Scalp; Surgical Procedures, Ope | 1964 |
[Exeresis in occipital neuralgia].
Topics: Adult; Cervical Vertebrae; Cicatrix; Female; Headache; Humans; Male; Middle Aged; Neuralgia; Neuroma | 1983 |
Treatment of occipital neuralgia.
Topics: Aged; Arteries; Cluster Headache; Humans; Ligation; Male; Neuralgia; Scalp | 1980 |
Occipital neuralgia in a football player: a case report.
Topics: Adult; Anesthetics, Local; Bupivacaine; Cervical Plexus; Diagnosis, Differential; Football; Headache | 1995 |
Treatment of occipital neuralgia by partial posterior rhizotomy at C1-3.
Topics: Adult; Cervical Vertebrae; Craniocerebral Trauma; Female; Follow-Up Studies; Humans; Laminectomy; Ma | 1995 |
Occipital neuralgia: symptoms, diagnosis, and treatment.
Topics: Diagnosis, Differential; Facial Pain; Female; Headache; Humans; Male; Neuralgia; Scalp | 1996 |
Sudden unconsciousness during a lesser occipital nerve block in a patient with the occipital bone defect.
Topics: Anesthetics, Local; Craniotomy; Dura Mater; Headache Disorders; Humans; Male; Middle Aged; Nerve Blo | 2001 |
Occipital neuralgia.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neck; Neuralgia; Scalp | 1977 |
Periodic migrainous neuralgia associated with an arteriovenous malformation.
Topics: Adult; Arteriovenous Malformations; Humans; Male; Migraine Disorders; Neuralgia; Scalp | 1975 |
51 cases of occipital neuralgia treated with acupuncture.
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Female; Humans; Male; Middle Aged; Neuralgia; Occipi | 1992 |
Myofascial pain may present clinically as occipital neuralgia.
Topics: Adult; Diagnosis, Differential; Female; Headache; Humans; Male; Middle Aged; Myofascial Pain Syndrom | 1986 |
A classification of headache.
Topics: Antidepressive Agents; Anxiety; Arteritis; Aspirin; Depression; Ergot Alkaloids; Facial Neuralgia; H | 1970 |